Navigation Links
Updated Overall Survival Data From Pivotal Herceptin Adjuvant,Studies in HER2-Positive Breast Cancer

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Genentech, Inc. (NYSE:DNA) today announced updated results from a joint analysis of two Phase III clinical trials studying Herceptin(R) (trastuzumab) for the adjuvant treatment of HER2-positive breast cancer. Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) showed that, with median follow-up of nearly three years, the addition of Herceptin to standard adjuvant therapy significantly improved overall survival in women with HER2-positive, node-positive breast cancer, compared to patients who received standard adjuvant therapy alone. Herceptin (with chemotherapy) is the first and only HER2-targeted therapy to demonstrate an overall survival benefit in adjuvant breast cancer, based on these study results, and in first-line metastatic HER2-positive breast cancer.

"These findings show, when using Herceptin for the adjuvant treatment of women with HER2-positive, node-positive breast cancer, patients live longer," said Hal Barron, M.D., Genentech's senior vice president, Development and chief medical officer. "These data further reinforce the use of Herceptin and chemotherapy as the foundation of care for women with this aggressive form of the disease."

Edith Perez, M.D., director of Mayo Clinic's Multidisciplinary Breast Clinic in Jacksonville, Fla., presented these updated data from the joint analysis of NCCTG N9831 and NSABP B-31 (Abstract #512 -- Monday, June 4, 2007, 9 a.m. CDT) studying Herceptin in the adjuvant setting. Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment - surgery with or without radiation therapy - with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease.

These two randomized, controlled Phase III studies evaluated four cycles of doxorubicin and cyclophosphamide followed by paclitaxel, either every t
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
5. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
6. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
7. Media Advisory: ACC Updated Schedule
8. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
9. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
10. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
11. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
Post Your Comments:
(Date:9/18/2014)... , Sept. 18, 2014  ADM Tronics ... DeNovi , Ph.D. to its corporate Advisory Board ... an instructor at the Harvard Medical School and ... Rome.  He received his Masters degree in Electronics ... Systems from the University of Bologna. After spending a ...
(Date:9/18/2014)... MiMedx Group, Inc. (NASDAQ: ... of patent protected regenerative biomaterials and bioimplants processed ... has entered into a distribution agreement with Zimmer, ... dehydrated human amnion/chorion membrane ("dHACM") allograft products to ... private label basis. The MiMedx dHACM ...
(Date:9/18/2014)... PLAINSBORO, N.J. , Sept. 18, 2014 ... the National Hemophilia Foundation,s (NHF) new three-year initiative, ... to people with hemophilia and their families/caregivers to ... can impede disease management. The curriculum for the ... Your Provider About Pain , focuses on improving ...
Breaking Medicine Technology:ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
(Date:9/18/2014)... "Medical staff need better ways to ... the patient's privacy," said one of two inventors from ... order to supply caregivers with the equipment they need ... prototype for The Helper to make it easier to ... patient onto his or her side. It also securely ...
(Date:9/18/2014)... One of the most capable and sophisticated ... ShandsCair Flight Program’s new EC155 B1, will be ... the Air Medical Transport Conference (AMTC), Sept. 22-24, in ... service ShandsCair EC155 and the Vanderbilt University LifeFlight ... highlight Airbus Helicopters broad, industry leading line-up of ...
(Date:9/18/2014)... Alan Mozes HealthDay ... When it comes to emergency room waiting times, patients seeking ... time staring down the clock than those seen at smaller ... of crowding and our ability to provide timely emergency care ... of the authors of the new research, Dr. Renee Hsia, ...
(Date:9/18/2014)... true: exercise is good for you. But new research ... have an added benefit for cancer patients undergoing chemotherapy. ... melanoma, found that combining exercise with chemotherapy shrunk tumors ... associate professor in the School of Nursing and director ... was the senior author on the study, which appears ...
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
Breaking Medicine News(10 mins):Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2
... 280 cases of malaria due to Plasmodium falciparum on the ... these reported cases, 264 have occurred in Kingston// , 12 ... Clarendon. There have been no reported deaths due to malaria. ... from the WHO Regional Office for the Americas coordinated by ...
... researchers based in the UK has found a way to ... potential for a new form of drug delivery// . ... of London, chemically modified carbon nanotubes by adding a range ... to enter a variety of cell types, including human cancer ...
... in the military have higher blood pressure, heart rates and ... . ,Researchers looked at 121 adolescents – including ... Iraq and 53 with a parent in the military but ... launched in March 2003 and nearly three months later when ...
... an independent risk factor for HIV infection, according to ... Sexually Transmitted Infections. The researchers conducted// a meta-analysis of ... looking at the link between smoking and progression to ... ,There is a growing recognition that smoking can increase ...
... Indian Affairs Committee on Thursday approved by voice ... to provide mental health services for suicide// prevention, ... Alaska Natives through expanded telemedicine systems, CongressDaily reports. ... committee Chair Byron Dorgan (D-N.D.), five tribes or ...
... used to treat diabetes and thought to hold great ... syndrome (PCOS), is less useful for helping women with ... with the infertility drug clomiphene, report researchers in an ... largest, most comprehensive effort yet to compare the two ...
Cached Medicine News:Health News:Carbon Nanoneedles For Drug Delivery 2Health News:Carbon Nanoneedles For Drug Delivery 3Health News:Carbon Nanoneedles For Drug Delivery 4Health News:Wartime Raises Stress, BP Rates in Military Offspring 2Health News:Smoking Increases Risk of HIV Acquisition 2Health News:Standard Therapy More Effective in Common Fertility Disorder 2Health News:Standard Therapy More Effective in Common Fertility Disorder 3
... for Candida albicans in only five ... two enzyme color reactions to produce ... read. AlbiQuicktm is performed on a ... Incubation time is only five minutes ...
... for small and large multi-specialty provider networks. ... check-out. Review the complete Patient History, from ... labs and charts all by one click ... immediately. Communicate electronically with the referring physicians ...
... meridianEMR is a revolutionary "blended model EMR ... medical records in your office and on-line ... of physicians and software engineers, meridianEMR combines ... create a highly modular medical EMR that ...
... an Automated Digital Cell Morphology and Informatics ... and transmission of White & Red Blood ... blood smears can be loaded at once, ... 60 per hour depending on the tests ...
Medicine Products: